Search

everythinglearnresearchcommunity

for

Search:↓

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.

A new tool simplifies alopecia areata severity scoring but needs validation.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

A SALT score of ≤ 20 indicates meaningful improvement in alopecia areata treatment.

The model improves understanding of androgen interactions by focusing on signal intensity and system capacity.

The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

The model improves understanding of androgen interactions by focusing on signal intensity and system capacity.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

Low-dose oral minoxidil effectively promotes hair growth with minimal side effects.

Oral difelikefalin significantly reduces itch in notalgia paresthetica.

Aminexil clinical 5 effectively reduces hair loss and is well-tolerated.

The Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata from other hair loss types but needs more validation.

Dexamethasone oral mini-pulse therapy effectively treats severe alopecia areata when JAK inhibitors can't be used.

Dermoscopy is useful for tracking alopecia areata treatment, with yellow dots and new vellus hairs being good indicators of hair regrowth.

Current methods for grading hair loss from cancer treatment are not accurate enough and need improvement.

LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.

LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.

Endoxan often causes hair loss, which usually starts in the third week of treatment.

After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.

Significant hair regrowth doesn't always mean complete hair recovery in alopecia areata.

Low-dose dutasteride effectively and safely promotes hair growth in men.

Intralesional triamcinolone acetonide effectively treats alopecia areata, as shown by significant improvements in hair regrowth and dermoscopic indicators.

The Swedish Hairdex-S is a reliable tool for assessing quality of life in Alopecia Areata patients.

Telogen effluvium most affects quality of life in alopecia patients.

Dutasteride effectively and safely treats male hair loss for over a year.

Spironolactone improved hair density and quality in women with hair loss.

Higher concentrations of dithranol can help regrow hair in severe alopecia areata.

Alfatradiol (0.025%) is an effective and safe treatment for hair loss in both women and men.